HUE039584T2 - PPAR-modulátor szulfonil-szubsztituált biciklusos vegyületek - Google Patents

PPAR-modulátor szulfonil-szubsztituált biciklusos vegyületek

Info

Publication number
HUE039584T2
HUE039584T2 HUE05851253A HUE05851253A HUE039584T2 HU E039584 T2 HUE039584 T2 HU E039584T2 HU E05851253 A HUE05851253 A HU E05851253A HU E05851253 A HUE05851253 A HU E05851253A HU E039584 T2 HUE039584 T2 HU E039584T2
Authority
HU
Hungary
Prior art keywords
ppar
modulators
sulfonyl
substituted bicyclic
bicyclic compounds
Prior art date
Application number
HUE05851253A
Other languages
English (en)
Inventor
Steward A Noble
Guy Oshiro
James W Malecha
Cunxiang Zhao
Carmen K M Robinson
Sergio G Duron
Michael Sertic
Andrew Lindstrom
Andrew Shiau
Christopher Bayne
Mehmet Kahraman
Boliang Lou
Steven Govek
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of HUE039584T2 publication Critical patent/HUE039584T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE05851253A 2004-10-29 2005-10-25 PPAR-modulátor szulfonil-szubsztituált biciklusos vegyületek HUE039584T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62325204P 2004-10-29 2004-10-29
US67981305P 2005-05-11 2005-05-11

Publications (1)

Publication Number Publication Date
HUE039584T2 true HUE039584T2 (hu) 2019-01-28

Family

ID=36071948

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE05851253A HUE039584T2 (hu) 2004-10-29 2005-10-25 PPAR-modulátor szulfonil-szubsztituált biciklusos vegyületek

Country Status (16)

Country Link
US (3) US7494999B2 (hu)
EP (1) EP1805158B1 (hu)
JP (1) JP5138377B2 (hu)
KR (1) KR101404930B1 (hu)
AR (1) AR052319A1 (hu)
AU (1) AU2005307006B2 (hu)
BR (1) BRPI0516435B1 (hu)
CA (1) CA2585172C (hu)
DK (1) DK1805158T3 (hu)
ES (1) ES2682282T3 (hu)
HU (1) HUE039584T2 (hu)
IL (1) IL182427A (hu)
MX (1) MX2007005205A (hu)
NZ (1) NZ589748A (hu)
RU (1) RU2384576C2 (hu)
WO (1) WO2006055187A1 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20070208026A1 (en) * 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
CA2521175A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
AU2005307006B2 (en) 2004-10-29 2012-05-03 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
WO2007024651A2 (en) * 2005-08-19 2007-03-01 Elan Pharmaceuticals, Inc. Bridged n-bicyclic sulfonamido inhibitors of gamma secretase
US8080579B2 (en) * 2005-10-03 2011-12-20 The Regents Of The University Of Michigan Compositions and methods for treatment of inflammatory bowel disease
WO2007047432A1 (en) * 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonamide derivatives as modulators of ppar
NZ566831A (en) * 2005-10-25 2011-09-30 Kalypsys Inc Salts of modulators of PPAR and methods of treating metabolic disorders
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
AU2007213671A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
WO2007090887A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3, 9-diazabicyclo [3.3. 1]nonane derivatives and their use as monoamine?neurotransmitter re-uptake inhibitors
CA2641678A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
US20070249519A1 (en) * 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
AR060937A1 (es) * 2006-05-16 2008-07-23 Kalypsys Inc Compuestos biciclicos sustituidos con sulfonilo como moduladores de ppar
WO2008043024A2 (en) * 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US20100183696A1 (en) * 2007-01-30 2010-07-22 Allergan, Inc Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2139845A1 (en) * 2007-02-26 2010-01-06 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
MX2009011415A (es) 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
CA2682671C (en) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
EP2098519A1 (en) 2007-05-31 2009-09-09 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
JP5417439B2 (ja) 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
CN102171189B (zh) 2008-07-31 2013-11-20 詹森药业有限公司 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶
EP2350008B1 (en) * 2008-10-09 2012-09-05 Bayer CropScience AG Method for the preparation of functionalized trihalomethoxy substituted pyridines
WO2010121212A2 (en) * 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN113880755A (zh) * 2021-08-27 2022-01-04 成都药明康德新药开发有限公司 2-溴-5-(三氟甲氧基)吡啶的制备方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929803A (en) * 1974-05-28 1975-12-30 Pfizer Aryl carboxylic acids
US4237130A (en) 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
DE3374408D1 (en) 1982-10-22 1987-12-17 Ciba Geigy Ag Benzodioxole derivatives, process for their preparation and pharmaceutical compositions containing them
EP0158596A3 (de) 1984-04-06 1986-08-13 Ciba-Geigy Ag Neue substituierte Benzodioxolderivate, Verfahren zu deren Herstellung und entsprechende pharmazeutische Zusammensetzungen
JPS6163671A (ja) 1984-09-05 1986-04-01 Shionogi & Co Ltd ２，３−ジヒドロベンゾフラン−５−スルホンアミド誘導体および降圧利尿剤
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
CA2293358C (en) 1997-06-17 2008-08-05 Schering Corporation Tricyclic sulfonamide inhibitors of farnesyl-protein transferase
EP1051176B1 (en) 1998-01-27 2006-11-22 Aventis Pharmaceuticals Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
MXPA01002173A (es) 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.
EP1122242B1 (en) 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
JP2003525203A (ja) 1999-03-22 2003-08-26 ダーウィン・ディスカバリー・リミテッド ヒドロキサムおよびカルボン酸誘導体
RU2256661C2 (ru) 1999-12-03 2005-07-20 Киото Фармасьютикал Индастриз, Лтд. Производные тетрагидроизохинолина и их соли и фармацевтическая композиция на их основе
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
GB0007907D0 (en) 2000-03-31 2000-05-17 Merck Sharp & Dohme Therapeutic agents
EP1324995A2 (en) * 2000-09-27 2003-07-09 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
EP1328510B1 (en) 2000-09-29 2013-11-20 TopoTarget UK Limited (e)-n-hydroxy-3-(3-sulfamoyl-phenyl)-acrylamide compounds and their therapeutic use
EP1354882A1 (en) 2000-12-27 2003-10-22 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
AU2002309435B2 (en) 2001-06-11 2008-08-14 Biovitrum Ab (Publ) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7157452B2 (en) * 2001-12-31 2007-01-02 Mgi Gp, Inc. Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses
ATE399012T1 (de) 2002-04-03 2008-07-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
US7629341B2 (en) 2002-06-12 2009-12-08 Symphony Evolution, Inc. Human ADAM-10 inhibitors
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
AR042120A1 (es) * 2002-11-25 2005-06-08 Schering Corp Ligandos receptores cannabinoides
DE10300099A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Indol-Phenylsulfonamid-Derivate
EP1597248B1 (en) 2003-02-14 2007-12-26 Eli Lilly And Company Sulfonamide derivatives as ppar modulators
US20070208026A1 (en) 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
CA2521175A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
ES2273282T3 (es) 2003-04-17 2007-05-01 Kalypsys, Inc. (3-(3-(2,4-bis-trifluorometil-bencil)-(5-etil-pirimidin-2-il)-amino)-propoxi)-fenil)-acetico y compuestos afines como moduladores de ppars y metodos de tratamiento de trastornos metabolicos.
BRPI0413059A (pt) 2003-07-29 2006-10-31 Xenon Pharmaceuticals Inc derivados de piridila e seu uso como agentes terapêuticos
US7605161B2 (en) 2003-07-30 2009-10-20 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7514436B2 (en) 2003-07-30 2009-04-07 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
SG145701A1 (en) 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Piperazine derivatives and their use as therapeutic agents
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20050203151A1 (en) 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
JP5026963B2 (ja) * 2004-06-22 2012-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド カルシウムチャネル調整用の複素環誘導体
WO2006014168A1 (en) 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
EP1799668A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
BRPI0515489A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
CA2580781A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
WO2006034446A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
AU2005307006B2 (en) 2004-10-29 2012-05-03 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20070190079A1 (en) 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
WO2007047432A1 (en) 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonamide derivatives as modulators of ppar
WO2007047431A2 (en) 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors
NZ566831A (en) * 2005-10-25 2011-09-30 Kalypsys Inc Salts of modulators of PPAR and methods of treating metabolic disorders
US20070219193A1 (en) 2006-03-17 2007-09-20 Kalypsys, Inc Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar
US20070249519A1 (en) 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
AR060937A1 (es) * 2006-05-16 2008-07-23 Kalypsys Inc Compuestos biciclicos sustituidos con sulfonilo como moduladores de ppar
US20080004281A1 (en) 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
US20080287477A1 (en) 2006-10-11 2008-11-20 Kalypsys, Inc. Novel Compounds as Modulators of Ppar
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
BRPI0516435B1 (pt) 2021-09-21
KR20070089786A (ko) 2007-09-03
AU2005307006B2 (en) 2012-05-03
NZ589748A (en) 2012-09-28
ES2682282T3 (es) 2018-09-19
RU2384576C2 (ru) 2010-03-20
RU2007116039A (ru) 2008-12-10
US7494999B2 (en) 2009-02-24
CA2585172C (en) 2014-08-12
BRPI0516435A (pt) 2008-09-02
WO2006055187A1 (en) 2006-05-26
CA2585172A1 (en) 2006-05-26
EP1805158B1 (en) 2018-06-27
US7834004B2 (en) 2010-11-16
KR101404930B1 (ko) 2014-06-09
JP2008518912A (ja) 2008-06-05
MX2007005205A (es) 2007-05-11
US7915253B2 (en) 2011-03-29
AU2005307006A1 (en) 2006-05-26
US20060167012A1 (en) 2006-07-27
IL182427A (en) 2016-02-29
IL182427A0 (en) 2007-07-24
EP1805158A1 (en) 2007-07-11
DK1805158T3 (en) 2018-08-06
JP5138377B2 (ja) 2013-02-06
US20090029971A1 (en) 2009-01-29
US20090264417A1 (en) 2009-10-22
AR052319A1 (es) 2007-03-14

Similar Documents

Publication Publication Date Title
IL182427A0 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar
IL181848A0 (en) Substituted bicyclic imidazo-3-yl-amine compounds
IL179376A0 (en) Compounds and compositions as ppar modulators
EP1745027A4 (en) COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS
IL179375A0 (en) Compounds and compositions as ppar modulators
SI1797037T1 (sl) Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida
IL181587A0 (en) Production of ??-abeta
IL209964A0 (en) Use of organic compounds
EP1756062A4 (en) COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS
HK1163672A1 (en) Processes for the preparation of compounds
IL223681A0 (en) Hydroxybenzoate salts of metanicotine compounds
EP1863473A4 (en) NEW USE OF LIGNAN CONNECTIONS
EP1749000A4 (en) BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
IL183647A (en) The heterocyclic compounds are converted into 3-ethylidenehydrazino
IL181185A0 (en) Novel polymorphs of azabicyclohexane
ZA200700162B (en) Novel heterocyclic compounds
IL181164A0 (en) Novel uses of 2-phenyl-substituted imidazotriazinone derivatives
EP1721158A4 (en) MODULATORS OF ANGIOGENESIS
GB0427403D0 (en) Novel compounds I
EP1961754A4 (en) BICYCLIC HETEROCYCLIC COMPOUND
EP1827449A4 (en) USE OF NOVEL ANTIBACTERIAL COMPOUNDS
ZA200608611B (en) Compounds and compositions as ppar modulators
IL180073A0 (en) Preparation of novel substituted haloarene compounds
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
EP1889619A4 (en) USE OF COMPOUNDS OF THIADIAZOLIDINE AS NEUROGENE AGENTS